* *










*

*


écrire à la sflm
écrire au webmestre

Dernière mise à jour 2018-11-23 

Carte des visites
réinitialisée après le congrès 2017
*

Articles scientifiques récents

    Ces articles sélectionnés ont été publiés au cours des 30 derniers jours.

    Vous trouverez ici le titre, la référence bibliographique, la date de publication, les auteurs, l'abstract, et un lien menant à la base de référencement où il est possible de consulter l'article entier, gratuit ou payant selon le cas.

     
  • Related Articles

    Extracorporeal Shockwave Therapy Combined with Drug Therapy in Chronic Pelvic Pain Syndrome - A Randomized Clinical Trial.

    Urol J. 2019 Apr 20;:

    Authors: Rayegani SM, Razzaghi MR, Raeissadat SA, Allameh F, Eliaspour D, Abedi AR, Javadi A, Rahavian AH

    Abstract
    PURPOSE: Chronic prostatitis/ chronic pelvic pain syndrome (CP/CPPS) is a nonspecific pelvic pain in the absence of signs of infection or other obvious local pathology for at least 3 of the last 6 months. The evidence for treatment is limited so the aim of this study is to investigate the effect of extracorporeal shock wave therapy (ESWT) combined with pharmacotherapy in the treatment of CP/CPPS.
    MATERIALS AND METHODS: In this randomized clinical  trial, 31 patients with CP/CPPS were investigated in two groups: the intervention group (n=16) was treated with a combination of an alfa-blocker, an anti-inflammatory agent, a muscle relaxant and a short course of antibiotic in combination with 4 sessions of focused ESWT (a protocol of 3000 impulses, 0.25 mJ/mm2  and 3 Hz of frequency); the control group (n=15) received the aforementioned pharmacotherapy with 4 sessions of sham-ESWT . Follow-up was performed 4 and 12 weeks following ESWT by using the Visual Analogue Scale (VAS), International index of Erectile function (IIEF) 5, National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) and International Prostate Symptom Score (IPSS) questionnaires. Post void residual (PVR) urine and maximum flow rate (Qmax) were also assessed in both groups.
    RESULTS: The patients mean age was 43.7 ±12.6 years. In both groups, the mean scores of NIH-CPSI (total and sub-domains) and VAS showed statistically significant improvements after 4 and 12 weeks compared to the baseline. (P < .001) In the intervention group, IPSS (mean difference: 4.25) and Qmax (mean difference: 2.22) were also significantly improved. (P < .001)  There was a significant improvement in NIH-CPSI (mean difference: 1.1) and VAS scores (mean difference: 1.1) in the intervention group as compared to the control group. (P < .01) Qmax, PVR and IIEF score were not statistically different in the two groups.
    CONCLUSION: ESWT in combination with pharmacotherapy could improve the treatment outcome in patients with CP/CPPS.

    PMID: 31004340 [PubMed - as supplied by publisher]

    Accès à la base de référencement pour cet article



    | Accueil | Actualités users | Applications | Congrès | Formation |
    | Inscriptions | Accès Membres | Industriels | Liens | Infos SFLM |